Literature DB >> 11602792

Chimeric papillomavirus-like particles expressing a foreign epitope on capsid surface loops.

Katharina Slupetzky1, Saeed Shafti-Keramat1, Petra Lenz1, Sabine Brandt1, Andreas Grassauer1, Margit Sara2, Reinhard Kirnbauer1.   

Abstract

Neutralization capsid epitopes are important determinants for antibody-mediated immune protection against papillomavirus (PV) infection and induced disease. Chimeric L1 major capsid proteins of the human PV type 16 (HPV-16) and the bovine PV type 1 (BPV-1) with a foreign peptide incorporated into several capsid surface loops self-assembled into pentamers or virus-like particles (VLP). Binding patterns of neutralizing monoclonal antibodies (MAb) and immunization of mice confirmed (i) that regions around aa 282-286 and 351-355 contribute to neutralization epitopes and identified the latter region as an immunodominant site and (ii) that placing a foreign peptide in the context of an assembled structure markedly enhanced its immunogenicity. Pentamers disassembled from wild-type HPV-16 and BPV-1 VLPs displayed some of the neutralization epitopes that were detected on fully assembled VLPs, but were deficient for binding a subset of neutralizing MAb that inhibit cell attachment.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11602792      PMCID: PMC3795388          DOI: 10.1099/0022-1317-82-11-2799

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  34 in total

1.  Structures of bovine and human papillomaviruses. Analysis by cryoelectron microscopy and three-dimensional image reconstruction.

Authors:  T S Baker; W W Newcomb; N H Olson; L M Cowsert; C Olson; J C Brown
Journal:  Biophys J       Date:  1991-12       Impact factor: 4.033

2.  Genetic applications of an inverse polymerase chain reaction.

Authors:  H Ochman; A S Gerber; D L Hartl
Journal:  Genetics       Date:  1988-11       Impact factor: 4.562

Review 3.  Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types.

Authors:  H zur Hausen
Journal:  Curr Top Microbiol Immunol       Date:  1994       Impact factor: 4.291

4.  Laboratory production in vivo of infectious human papillomavirus type 11.

Authors:  J W Kreider; M K Howett; A E Leure-Dupree; R J Zaino; J A Weber
Journal:  J Virol       Date:  1987-02       Impact factor: 5.103

5.  In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16.

Authors:  W I White; S D Wilson; W Bonnez; R C Rose; S Koenig; J A Suzich
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

6.  Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16.

Authors:  X S Chen; R L Garcea; I Goldberg; G Casini; S C Harrison
Journal:  Mol Cell       Date:  2000-03       Impact factor: 17.970

7.  Quantitative disassembly and reassembly of human papillomavirus type 11 viruslike particles in vitro.

Authors:  M P McCarthy; W I White; F Palmer-Hill; S Koenig; J A Suzich
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

8.  Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles.

Authors:  R Kirnbauer; J Taub; H Greenstone; R Roden; M Dürst; L Gissmann; D R Lowy; J T Schiller
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

9.  Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus.

Authors:  N D Christensen; C A Reed; N M Cladel; R Han; J W Kreider
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

10.  A neutralizing epitope of human papillomavirus type 11 is principally described by a continuous set of residues which overlap a distinct linear, surface-exposed epitope.

Authors:  S W Ludmerer; D Benincasa; G E Mark; N D Christensen
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

View more
  24 in total

1.  Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7.

Authors:  Jerri do Carmo Caldeira; Alexander Medford; Rhonda C Kines; Christopher A Lino; John T Schiller; Bryce Chackerian; David S Peabody
Journal:  Vaccine       Date:  2010-04-29       Impact factor: 3.641

Review 2.  Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins.

Authors:  Xiao Zhang; Lu Xin; Shaowei Li; Mujin Fang; Jun Zhang; Ningshao Xia; Qinjian Zhao
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Combinatorial approach to hepadnavirus-like particle vaccine design.

Authors:  Jean-Noel Billaud; Darrell Peterson; Margaret Barr; Antony Chen; Matti Sallberg; Fermin Garduno; Phillip Goldstein; Wendy McDowell; Janice Hughes; Joyce Jones; David Milich
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

4.  Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles.

Authors:  Timothy D Culp; Christin M Spatz; Cynthia A Reed; Neil D Christensen
Journal:  Virology       Date:  2007-01-12       Impact factor: 3.616

Review 5.  [HPV vaccines. Prophylactic vaccines from virus-like particles].

Authors:  R Kirnbauer
Journal:  Hautarzt       Date:  2007-06       Impact factor: 0.751

Review 6.  Developments in L2-based human papillomavirus (HPV) vaccines.

Authors:  Christina Schellenbacher; Richard B S Roden; Reinhard Kirnbauer
Journal:  Virus Res       Date:  2016-11-23       Impact factor: 3.303

7.  Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16.

Authors:  Arvind Varsani; Anna-Lise Williamson; Debbie de Villiers; Inga Becker; Neil D Christensen; Edward P Rybicki
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

8.  Serological relationship between cutaneous human papillomavirus types 5, 8 and 92.

Authors:  Alessandra Handisurya; Ratish Gambhira; Christina Schellenbacher; Saeed Shafti-Keramat; Ola Forslund; Michel Favre; Reinhard Kirnbauer
Journal:  J Gen Virol       Date:  2009-01       Impact factor: 3.891

9.  Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines.

Authors:  Christina Schellenbacher; Richard Roden; Reinhard Kirnbauer
Journal:  J Virol       Date:  2009-07-29       Impact factor: 5.103

10.  Antigenic presentation of heterologous epitopes engineered into the outer surface-exposed helix 4 loop region of human papillomavirus L1 capsomeres.

Authors:  Yoshihiko Murata; Paula M Lightfoote; Robert C Rose; Edward E Walsh
Journal:  Virol J       Date:  2009-06-18       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.